Xanax (Alprazolam) Withdrawal Timeline and How to Taper Off Safely

This article is education, not medical advice, and it is not a substitute for a conversation with the prescriber who knows your history. Benzodiazepine withdrawal is different from many other withdrawals because it can be dangerous. Stopping alprazolam abruptly, or dropping the dose too fast, can trigger severe reactions including seizures, which can be life-threatening. The FDA added a Boxed Warning to the entire benzodiazepine class in 2020 specifically about dependence and withdrawal, and it is clear on one point: do not stop suddenly, use a gradual taper.

So please do not use anything here to quit on your own or to speed yourself up. Use it to understand what is happening to you, to feel less alone, and to walk into your prescriber's office with informed, specific questions. If you ever feel suicidal or are in crisis, contact your local emergency number or a crisis line right away. In the US you can call or text 988.

Alprazolam works by enhancing GABA, your brain's main calming signal. Used regularly for more than a few weeks, the brain adapts by dialing down its own GABA system and turning up excitatory activity to keep balance. That adaptation is physical dependence, and it can begin quickly. The FDA notes that physical dependence can develop after just days of consistent use.

What makes Xanax especially tricky is its short half-life. The FDA label puts the mean elimination half-life at about 11 hours, far shorter than long-acting benzos like diazepam (Valium), which can last days. A short half-life means the drug clears fast, so the level in your blood rises and falls sharply between doses. Many people feel this as interdose withdrawal: anxiety, dread, or shakiness creeping in a few hours before the next dose is due. It can feel like worsening anxiety when it is partly the medication leaving and the nervous system rebounding. This is also why splitting alprazolam into more frequent daily doses, or switching to a longer-acting benzo, is sometimes part of a plan.

Everyone is different, and your dose, how long you have taken it, your physiology, and your taper speed all shape the picture. With that said, here is a rough map so the experience feels less mysterious.

• Acute phase (first days to a few weeks after a cut or stop): Because alprazolam is short-acting, symptoms can appear within hours to a day or two of a meaningful reduction. Common experiences include rebound anxiety, insomnia, irritability, restlessness, muscle tension, tremor, sweating, racing heart, sensory sensitivity, and trouble concentrating. After an abrupt stop this is also when seizure risk is highest, which is exactly why tapering matters.
• Subacute phase (weeks to a few months): Symptoms often soften and become more uneven. Many people describe windows and waves, good stretches interrupted by harder days that arrive without obvious cause. This pattern is well documented in the recovery communities and is not a sign you are going backward.
• Protracted phase (a smaller subset of people, months and sometimes longer): Some people have lingering symptoms that fade slowly over time. This is more likely after fast tapers or cold-turkey stops, which is part of why a slow approach is worth the patience.

If you have tried to come off Xanax before and it went badly, please hear this clearly. The most common reason tapers fail is that the steps were too big and too fast, not that you were weak or did it wrong.

Here is the science behind that. The relationship between benzodiazepine dose and its effect on GABA-A receptors is hyperbolic, not linear. At higher doses, a large milligram cut removes only a small slice of receptor effect. But near the bottom, the same size cut removes a huge slice, because that is the steep part of the curve. This is why the last leg of a taper, the small doses, is so often where people get blindsided, and why standard advice like cutting by a fixed amount each week tends to fall apart at the end.

Hyperbolic tapering, described in detail in the Maudsley Deprescribing Guidelines by Horowitz and Taylor, solves this by making each reduction a percentage of your current dose rather than a fixed milligram amount. The cuts get smaller and smaller as the dose drops, so the effect on your receptors comes off in even, tolerable steps the whole way down. A common starting point in the literature is reducing by something like 5 to 10 percent of the current dose at each step, with time to stabilize in between. When people slow down to this kind of pace, the same taper that once felt impossible often becomes manageable.

A taper is not a fixed prescription, it is a process you and your prescriber adjust based on how you feel. A few principles from the deprescribing literature and the Ashton Manual:

• Reduce by percentages, not flat amounts. Each step is a small fraction of your current dose, so the steps shrink as you descend. Many people land somewhere around 5 to 10 percent per step.
• Hold until stable before the next cut. Horowitz and Taylor suggest spacing reductions enough to see whether symptoms settle, often a few weeks per step. If a cut hits hard, you stay put longer, or step back up and go slower. There is no prize for rushing.
• Consider a switch to a longer-acting benzo. The Ashton Manual, written by Professor Heather Ashton, often converts short-acting benzos like alprazolam to an equivalent dose of diazepam, because its long half-life gives smoother blood levels and makes tiny end-stage reductions easier. As a rough guide the Ashton Manual treats roughly 0.5 mg of alprazolam as similar to about 10 mg of diazepam, but conversions vary between people and are a prescriber decision, not a DIY calculation.
• Expect to spend the most time at the bottom. Because of the hyperbolic curve, the final stretch from low doses to zero usually takes the longest. That is normal and expected, not a setback.

Here is the part many guides gloss over. The pharmacology says to make ever-smaller cuts near the end, but a Xanax tablet only comes in so many sizes, and the smallest common one is 0.25 mg. So how do you actually take a dose like 0.2 mg, or 0.11 mg? This is a real, physical problem, and solving it is where a lot of tapers live or die.

The community-tested toolkit includes:

• Oral liquids. A compounding pharmacy can make alprazolam (or diazepam, if you have switched) into a liquid suspension, for example 1 mg/mL, so you can measure precise small doses with an oral syringe. Diazepam also comes as a commercial 1 mg/mL solution. Liquids are the cleanest way to make tiny, exact reductions.
• Tablet splitting. Useful for larger steps, but pill splitters get imprecise with small fragments, and alprazolam is not evenly distributed in every tablet, so this gets unreliable at the bottom.
• Liquid titration at home. Dispersing a tablet in a measured volume of liquid and drawing off a precise amount. The recovery communities have detailed how-to guides for this.
• Bead or content counting. More relevant to extended-release or capsule formulations than to standard Xanax tablets, but part of the broader benzo toolkit.

The Benzodiazepine Information Coalition, BenzoBuddies, and the Ashton Manual all cover these methods in depth, and they are excellent, free resources to read alongside your prescriber's guidance.

Some of the most useful, compassionate, and clinically grounded knowledge about coming off Xanax did not come from drug companies, it came from people who lived it and from a handful of dedicated clinicians and researchers. It is worth knowing them by name:

• The Ashton Manual (benzo.org.uk), the foundational guide to benzodiazepine withdrawal and the diazepam-switch approach.
• BenzoBuddies, a large peer forum where people share real taper logs, the windows-and-waves pattern, and end-stage liquid methods.
• Surviving Antidepressants, which despite the name covers benzodiazepines and helped popularize tapering by a percentage of the current dose.
• Inner Compass Initiative and The Withdrawal Project, for plain-language guidance and connection.
• The Maudsley Deprescribing Guidelines by Horowitz and Taylor, the clinical reference that put hyperbolic tapering on a firm pharmacological footing, and the Benzodiazepine Information Coalition for practical strategy.

None of these replaces your prescriber, and the strongest plans usually combine all three: the lived wisdom of the communities, the science of the guidelines, and a clinician who can prescribe the liquids and adjust as you go.

Understanding the curve is one thing. Translating it into exact doses for next Tuesday, with the right liquid concentration and syringe markings, is another, and it is a lot to hold in your head while you are also managing symptoms.

This is the one place we will mention that Subside exists. The app can take your current dose, history, and how you are feeling and turn the hyperbolic approach into a personalized, day-by-day schedule, including the small end-of-taper steps and the physical measuring instructions, that you can review and adjust with your prescriber. It is meant to be a calm companion to that relationship, not a replacement for it. If a simpler pen-and-paper plan from your clinician works for you, that is completely fine too. The method matters more than the tool: go slow, cut by percentages, hold until steady, and be patient at the bottom.